Cite
HARVARD Citation
Garon, E. et al. (n.d.). 3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy. European journal of cancer. pp. S621-. [Online].